CompuMed Financials
| CMPD Stock | USD 3.02 0.25 7.65% |
CompuMed |
Understanding current and past CompuMed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CompuMed's financial statements are interrelated, with each one affecting the others. For example, an increase in CompuMed's assets may result in an increase in income on the income statement.
Please note, the presentation of CompuMed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CompuMed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CompuMed's management manipulating its earnings.
CompuMed Stock Summary
CompuMed competes with Healthlynked Corp, Mosaic Immunoengineerin, and Vycor Medical. CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California. Compumed operates under Health Information Services classification in the United States and is traded on OTC Exchange. It employs 8 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US2049144023 |
| Business Address | 5777 West Century |
| Sector | Health Care Technology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.compumed.net |
| Phone | 310 258 5000 |
| Currency | USD - US Dollar |
CompuMed Key Financial Ratios
There are many critical financial ratios that CompuMed's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that CompuMed reports annually and quarterly.| Return On Equity | -0.3 | |||
| Return On Asset | -0.13 | |||
| Target Price | 2.05 | |||
| Beta | 0.95 | |||
| Z Score | 39.4 |
CompuMed Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CompuMed's current stock value. Our valuation model uses many indicators to compare CompuMed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CompuMed competition to find correlations between indicators driving CompuMed's intrinsic value. More Info.CompuMed is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CompuMed's earnings, one of the primary drivers of an investment's value.CompuMed Systematic Risk
CompuMed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CompuMed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on CompuMed correlated with the market. If Beta is less than 0 CompuMed generally moves in the opposite direction as compared to the market. If CompuMed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CompuMed is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CompuMed is generally in the same direction as the market. If Beta > 1 CompuMed moves generally in the same direction as, but more than the movement of the benchmark.
CompuMed December 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CompuMed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CompuMed. We use our internally-developed statistical techniques to arrive at the intrinsic value of CompuMed based on widely used predictive technical indicators. In general, we focus on analyzing CompuMed Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CompuMed's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 34.52 | |||
| Value At Risk | (8.68) | |||
| Potential Upside | 11.11 |
Complementary Tools for CompuMed Pink Sheet analysis
When running CompuMed's price analysis, check to measure CompuMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CompuMed is operating at the current time. Most of CompuMed's value examination focuses on studying past and present price action to predict the probability of CompuMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CompuMed's price. Additionally, you may evaluate how the addition of CompuMed to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |